Biotech Catalysts to Watch: Key Developments for September 2026

September 2026 brings several biotech events that might shake up the market. Seven catalysts, including two PDUFA dates, are on the docket. Investors should zero in on these developments due to their potential to alter company valuations and therapeutic fields.

The full biotech catalysts to watch

IGALMI® (BTAI): PDUFA Date on November 14, 2026

IGALMI® (dexmedetomidine) from BioXcel Therapeutics (BTAI) faces a PDUFA date on November 14, 2026. This could transform treatment for acute agitation in bipolar disorders and schizophrenia. As a selective α2A-adrenergic receptor agonist, it's the first orally dissolving sublingual film in a space dominated by invasive options like benzodiazepines. Its probability of approval (PoA) is just 10%, highlighting uncertainties about the supplemental NDA for Alzheimer's-related agitation. The market needs better treatments, as current ones often have adverse effects and require invasive administration. The TRANQUILITY II trial showed statistically significant reductions in agitation, offering some hope. Yet, safety concerns about QT prolongation and hypotension, especially in vulnerable populations, remain. The PDUFA decision will be pivotal; investors should watch this closely as it might change psychiatric treatment protocols.

Namodenoson (CANF): Phase 2a Results Due by December 31, 2026

Namodenoson from Can-Fite BioPharma (CANF) is in Phase 2a for advanced pancreatic ductal adenocarcinoma (PDAC), with results expected by December 31, 2026. Its PoA is 19%, reflecting its early stage and lack of FDA designations for this use. As a first-in-class small molecule targeting the adenosine A3 receptor, Namodenoson introduces a new mechanism of action. Early results show durable overall survival, but full efficacy metrics are still pending, making this a high-risk investment. The global market for advanced PDAC is about $15 billion, driven by high disease incidence and inadequate treatments, emphasizing the unmet medical need. Investors should focus on the upcoming Phase 2a results, as they will be crucial for the drug's future direction. The absence of regulatory designations for PDAC also raises questions about the possibility of accelerated review or approval, complicating the investment landscape.

Deramiocel (CAP-1002, CAPR): PDUFA Date on November 22, 2026

Deramiocel (CAP-1002) from Capricor Therapeutics (CAPR) is up for review with a PDUFA date of November 22, 2026. This allogeneic cell therapy targets Duchenne muscular dystrophy (DMD) and its related cardiomyopathy. The PoA is 42%, supported by its first-in-class status and the significant unmet need in DMD treatment. The global DMD treatment market is projected to hit about $3.8 billion by 2026, highlighting the commercial opportunity. However, the advisory committee has raised concerns about the statistical evidence, which might affect the FDA's decision. Despite manageable safety data, efficacy remains a pivotal concern. This PDUFA date is important; investors should keep an eye on any additional FDA communications that could influence the outcome. If approved, Deramiocel could become a core treatment in DMD due to its unique mechanism.

CAD-1005 (CVKD): Phase 2 Results on September 11, 2026

CAD-1005 from Cadrenal Therapeutics (CVKD) is an intravenous 12-lipoxygenase inhibitor aimed at heparin-induced thrombocytopenia (HIT) and cardiac surgery-associated acute kidney injury (CSA-AKI). With Phase 2 results due on September 11, 2026, the PoA is 28%. Preliminary results for HIT show promise, with over a 25% reduction in thrombotic events compared to placebo. However, the absence of detailed statistical metrics raises questions about data robustness. The market for HIT and CSA-AKI is substantial, exceeding $1 billion, yet both lack approved disease-modifying therapies. The Phase 2 results will be key in determining the drug's path forward. Investors should also watch for the start of a Phase 3 registration study for HIT, which could clarify the drug's potential and market position.

EYP-1901 (EYPT): Anticipated Results on September 24, 2026

EYP-1901 (Vorolanib Intravitreal Insert) from EyePoint Pharmaceuticals (EYPT) is set for a crucial data release on September 24, 2026, targeting neovascular age-related macular degeneration (nAMD). With a moderate PoA, trial results could heavily influence the drug's future in a crowded field. Current nAMD treatments are extensive, and EYP-1901's unique delivery method could offer a needed alternative. Investors should watch for data validating its efficacy and safety, as this will determine its market potential.

SIL204 (SLXN): Key Data Release on December 31, 2026

SIL204 from Salix Pharmaceuticals (SLXN) will report results for locally advanced pancreatic cancer by December 31, 2026. With a low PoA, the drug faces significant hurdles in a crowded oncology market. Efficacy and safety data will be critical in assessing its viability. The anticipated data will inform investors about the drug's position in the treatment landscape and its potential to address unmet needs in pancreatic cancer therapy.

ZYNLONTA (ADCT): Significant Catalyst on December 31, 2026

ZYNLONTA (loncastuximab tesirine-lpyl) combined with rituximab is an exciting catalyst, with results expected by December 31, 2026, for second-line diffuse large B-cell lymphoma (DLBCL). With a high PoA, this combination could redefine treatment protocols in a tough area. The competitive landscape is fierce, but the combination's potential efficacy makes it a key event for investors. Monitoring this development is essential, as it could lead to significant shifts in DLBCL treatment paradigms.

The bottom line

The biotech catalysts in September 2026 offer both opportunities and risks. Investors should stay alert and informed as these events unfold.